We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Ultrasensitive Sensor Detects Down Syndrome in Womb

By HospiMedica International staff writers
Posted on 28 Feb 2019
A new biosensor could someday be used to detect fetal Down syndrome DNA in pregnant women's blood, according to a new study.

Developed by researchers at Peking University (Beijing, China), the National Research Institute for Family Planning of China (NHC; Beijing) and the Chinese Academy of Sciences (Shenyang, China), the highly sensitive DNA biosensors are based on a field-effect transistor (FET) fabricated using chemical vapor deposition grown monolayer molybdenum disulfide (MoS2) films. More...
The MoS2 is functionalized with gold nanoparticles of an optimized size and ideal density, allowing the DNA biosensor to probe for specific target immobilized on the nanoparticles.

Study results revealed that the fabricated FET biosensors were able to reliably detect target DNA fragments (chromosome 21 or 13) with a detection limit below 100 aM, a high response rate of up to 240%, and a high specificity, which satisfy the requirement for the screening of Down syndrome. In addition, a real-time in-vitro test was conducted to show that the biosensor clearly responds to the target DNA at concentrations as low as one fM. The study was published on February 13, 2019, in Nano Letters.

“Our approach shows the potential for detecting the over-expression of chromosome 21 in the peripheral blood of pregnant women,” concluded lead author Jingxia Liu, PhD, of Peking University, and colleagues. “Eventually, the test could be used to compare levels of chromosome 21 DNA in blood with that of another chromosome, such as 13, to determine if there are extra copies, suggesting a fetus has Down syndrome.”

Down syndrome, which is characterized by variable degrees of intellectual and developmental problems, is caused by the presence of an extra copy of chromosome 21. To screen for the condition, pregnant women can have ultrasound scans or indirect blood biomarker tests, but misdiagnosis rates are high. Amniocentesis can provides a definitive diagnosis, but the procedure poses risks to both the pregnant woman and the fetus. And while the emerging method of whole-genome sequencing is highly accurate, it is a slow and expensive process.

Related Links:
Peking University
National Research Institute for Family Planning of China
Chinese Academy of Sciences


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The new 3D heart mapping system visualizes all four chambers in real time (Photo courtesy of UPV)

Whole-Heart Mapping Technology Provides Comprehensive Real-Time View of Arrhythmias

Cardiac arrhythmias can be difficult to diagnose and treat because current mapping systems analyze the heart one chamber at a time. This fragmented view forces clinicians to infer electrical activity they... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.